SynthesisHealth and quality of life outcomes2026
Quality of life in patients with pulmonary arterial hypertension: A systematic review and meta-analysis.
Synthesis in Health and quality of life outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Paradigm Shift of HCurrent issues in molecular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary arterial hypertension (PAH) is a rare incurable disease characterized by pulmonary artery remodeling, which may eventually lead to right ventricular failure and death. Despite advancements in targeted therapies, PAH remains life-threatening with significant impact on patients’ quality of life (QoL). The importance of patient-reported outcome measures (PROMs) in assessing health-related QoL has been increasingly recognized, but their implementation remains inconsistent in clinical practice. This systematic review aims to assess and synthesize the available evidence on the impact of PAH on patients’ QoL measured by PROMs.
methodsA systematic review was conducted following PRISMA guidelines. Studies were identified through searches in CINAHL, EMBASE, Web of Science, PubMed, Scopus, and BVS. Inclusion criteria encompassed observational studies and RCTs with non-pharmacological interventions assessing QoL in PAH patients. RCTs involving drugs were excluded. Risk of bias was assessed using the Joanna Briggs Institute (JBI) appraisal tools. A meta-analysis was performed using a random-effects model.
resultsA total of 3271 studies were retrieved; 44 met inclusion criteria. PROMs like SF-36 (14 studies), SF-12 (2), CAMPHOR (9), EQ-5D (7), and EmPHasis-10 (13) were utilized. Findings highlight a dichotomy in QoL outcomes, with significant physical impairments but relatively preserved mental health scores. Subgroup analyses revealed substantial heterogeneity, emphasizing the need for standardized tools.
conclusionsThis review underscores the critical role of PROMs in understanding QoL in PAH patients. Findings advocate for integrating PROMs into clinical assessments and standardizing methodologies. REGISTRATION: The protocol was registered in PROSPERO (CRD42022292145).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.